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Abstract
Background: Besides its well-established role in nerve cell survival and adaptive plasticity, brain-derived neurotrophic factor
(BDNF) is also involved in energy homeostasis and cardiovascular regulation. Although BDNF is present in the systemic
circulation, it is unknown whether plasma BDNF correlates with circulating markers of dysregulated metabolism and an
adverse cardiovascular profile.
Methodology/Principal Findings: To determine whether circulating BDNF correlates with indices of metabolic and
cardiovascular health, we measured plasma BDNF levels in 496 middle-age and elderly subjects (mean age ,70), in the
Baltimore Longitudinal Study of Aging. Linear regression analysis revealed that plasma BDNF is associated with risk factors
for cardiovascular disease and metabolic syndrome, regardless of age. In females, BDNF was positively correlated with BMI,
fat mass, diastolic blood pressure, total cholesterol, and LDL-cholesterol, and inversely correlated with folate. In males, BDNF
was positively correlated with diastolic blood pressure, triglycerides, free thiiodo-thyronine (FT3), and bioavailable
testosterone, and inversely correlated with sex-hormone binding globulin, and adiponectin.
Conclusion/Significance: Plasma BDNF significantly correlates with multiple risk factors for metabolic syndrome and
cardiovascular dysfunction. Whether BDNF contributes to the pathogenesis of these disorders or functions in adaptive
responses to cellular stress (as occurs in the brain) remains to be determined.
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Introduction
The development, survival and plasticity of the vertebrate
nervous system rely on the secretion of neurotrophins by neural
cells. Brain-derived neurotrophic factor (BDNF) belongs to the
neurotrophin family and exerts its actions by activating the
tropomyosin-related kinase receptor B (TrkB) [1]. BDNF is
involved in learning and memory formation [2] and reduced
BDNF levels in various brain regions have been implicated in the
pathogenesis of neurodegenerative and psychiatric disorders [3]. It
has more recently become apparent that BDNF is present outside
of the central nervous system (CNS) and circulates systemically
[4,5]. Studies using animal models have shown that conditions
linked to metabolic and cardiovascular dysfunction, e.g. obesity,
diabetes, heart disease, can be modified by manipulation of BDNF
in the brain and in the peripheral circulation [6]. In rodents, it has
been suggested that BDNF can cross the blood-brain barrier [7]
and one study indicated that cortical levels of BDNF correlate with
platelet BDNF concentration [8]. However, a recent study showed
that BDNF concentration in the plasma is unrelated to levels
found in the cortex and hippocampus [9].
Considerable evidence supporting a role for BDNF in energy
homeostasis has been derived from experimental murine models.
While homozygosity for the BDNF gene deletion is lethal [10],
BDNF haploinsufficiency is associated with hyperphagia and
obesity [6] and elevated endocrine appetite/dietary factors [11].
Consistent with data from BDNF heterozygotic mice, peripheral
injection of BDNF causes a marked decrease in food intake and
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metabolic control, BDNF and its receptor, TrkB, are abundantly
expressed in hypothalamic areas associated with energy balance,
such as the paraventricular nucleus, arcuate nucleus and
ventromedial nucleus [13]. Moreover, BDNF deficiency in
humans appears to induce phenotypes similar to those of animal
models. Severe hyperphagia and childhood onset obesity develop
in individuals with BDNF haploinsufficiency [14]. Furthermore, a
de novo missense mutation of the gene that encodes TrkB is
associated with childhood obesity [15].
While there is significant evidence suggesting a link between
BDNF expression and energy regulation, the effects of BDNF on
the cardiovascular system are not as well understood. BDNF is
involved in the development and survival of the arterial
baroreceptor system [16], and when injected in the rostrolateral
medulla causes a blood pressure spike [17]. Additionally,
embryonic BDNF deficiency severely impairs the development
of intramyocardial vessels and can lead to cardiac hypocontracti-
lity [18]. Moreover, BDNF expression is significantly increased in
atherosclerotic coronary arteries, compared to nonatherosclerotic
coronary arteries from control subjects [19], and one study has
demonstrated that there are reduced plasma BDNF levels in
patients with acute coronary syndromes [20].
In spite of evidence from animal studies showing effects of
BDNF on energy regulation and the cardiovascular system, little is
known about BDNF plasma levels in human health and
pathological states. In this study, we address this important issue,
by measuring plasma BDNF levels in a cohort of healthy middle
age and elderly subjects enrolled in the Baltimore Longitudinal
Study of Aging (BLSA), and attempt to identify physiological and
pathological parameters that may be correlated with plasma
BDNF levels.
Materials and Methods
Subjects
The Baltimore Longitudinal Study of Aging (BLSA) is a
prospective study of community-dwelling volunteers who were
healthy at the time of enrollment; the study has been conducted by
the National Institute on Aging without interruption since 1958
[21]. Institutional Review Board written approval was obtained
from the National Institute on Aging, and informed written
consent was obtained from all participants. All samples collected
were analyzed in a de-identified manner. Participants returned to
the National Institute on Aging Clinical Unit in Baltimore,
Maryland, at regular intervals for 2–3 days of medical,
physiological, and psychological examinations. Descriptive char-
acteristics of the study cohort are reported in Table 1. Study
participants with long-term chronic disease, severe allergies or un-
controlled medical conditions were not included in the analytical
study. Plasma BDNF levels were measured in 245 males and 251
females; genders were analyzed separately. This study was
performed in an aged population; the average male was 71.9
years of age and the average age of the female cohort was 70.3
years of age. Blood samples were drawn from subjects in the
morning after an overnight fast.
Variables measured
Plasma BDNF:. Plasma BDNF levels were measured as
described previously [22], using a commercially available ELISA
kit (Promega) with the range of sensitivity from 7.8 to 500 pg/mL
and inter-assay variation measured at 8.8% (low concentration),
2.9% (medium concentration) and 2.2% (high concentration).
Briefly, blood samples were centrifuged at 3000 rpm for
30 minutes at 4uC. Plasma was carefully collected and was snap
frozen on dry ice and subsequently stored at 280uC, until used for
further analyses. For BDNF measurements, the plasma samples
were diluted 1:5 in block and sample buffer provided by the kit.
The BDNF plate was coated with primary BDNF antibody
overnight, the following day block and sample buffer was added to
each well for 1 hour, and subsequently the standards and samples
were added for 2 hours. Thereafter, anti-human BDNF pAb
secondary antibody was added for 2 hours and the anti-Ig Y HRP
conjugate was added for 1h. Then, TMB One solution was added
to each well for 5 minutes and the reaction was stopped with
hydrochloric acid. The plate was analyzed within 30 minutes, at
450 nm. All reagents necessary were provided by the
manufacturer.
Blood pressure and body mass index:. Blood pressure
(BP) determinations were performed in the morning, after a light
breakfast, with participants in the seated position and following a
5-minute resting time. BP was measured three times in both arms
with a mercury sphygmomanometer, and the average of the
second and third measurements on both the right and left arms
were used for the analyses. Height and weight were objectively
measured and body mass index (BMI) was calculated as body
weight (kg)/height (m
2).
Fasting plasma lipids and glucose:. Plasma triglycerides
andtotalcholesterollevelsweredeterminedbyanenzymaticmethod
(ABA-200 ATC Biochromatic Analyzer, Abott Laboratories). Low
density lipoprotein (LDL) cholesterol was estimated by the
Friedewald formula for those participants with triglycerides not
greater than 400 mg/dL. Glucose levels were measured by the
glucose oxidase method (Beckman Instruments Inc.).
Plasma hormone, sex hormone binding globulin, and
folate levels:. Free triiodo-thyronine (FT3) levels were
measured using a competitive-binding immunoassay (Beckman
Coulter DX1800) by the Mayo Clinic Laboratories, as described
previously [23]. Adiponectin was measured by radioimmuno
assay, according to the manufacturer’s instructions (Millipore).
Bioavailable testosterone was determined by a modification of the
ammonium sulfate precipitation method as previously described
[24]. Sex hormone binding globulin (SHBG) was measured using
an enzyme-linked immunosorbent assay using commercially
available kits (DRG Diagnostics, Marburg, Germany). Free
testosterone was calculated from total testosterone and SHBG by
Table 1. Descriptive characteristics of study subjects.
Variable Males Females
Total 245 251
Mean age (years) 71.960.79 70.360.76
Weight (kg) 82.660.83 70.260.96
BMI (kg/m
2) 27.060.25 26.960.35
Insulin use 3.2 0.44
Anti-depressant use 4.4 6.1
DM self-report 14.6 3.9
DM medication 15.1 5.2
Angina pectoris 15.9 5.7
Myocardial ischemia 4.9 3.9
Current smoker 4.8 2.6
Body Mass Index (BMI), Diabetes Mellitus (DM). Values for age, weight, and BMI
are the mean 6 S.E.M.
doi:10.1371/journal.pone.0010099.t001
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determined by competitive protein-binding assays (Modular
Analytics E170, Roche Diagnostics).
Statistical analyses:. Linear regression analysis, for
individual subject plasma BDNF levels against the multiple
parameters measured in the BLSA test population, was performed
for all test subjects whose BDNF levels fell within a normal
distribution (male and female separately) for the total BDNF
measurements. This exclusion criteria (95% confidence) resulted in
the removal of four subjects from both male or female BLSA subject
groups. Standard linear regression analyses were performed using
GraphPad Prism (version 3). Statistical significance was taken at the
0.05 level with respect to the linear correlations’ deviation from a
zero slope. Linear regression correlation analysis was performed for
plasma BDNF levels versus all of the parameters measured in BLSA.
Linear correlations that failed to pass the cut-off criteria of p,0.05
are listed in Supplementary Table S1.
Results
Plasma BDNF, gender, and age
Across the two gender populations in our study the plasma
BDNF levels were significantly higher in female subjects than in
males (p,0.05; Figure 1A). In both male and subjects, a significant
negative correlation was seen between BDNF and age, with older
males and females having lower plasma BDNF levels (males:
p=0.0501, R
2=0.0157; females: p=0.022, R
2=0.02244; Fig. 1B,
C, Table 2).
Elevated BDNF levels are correlated with risk factors for
heart disease and metabolic syndrome in both male and
female subjects
Although the exact nature of the relationship between BDNF
and heart disease is unknown, several studies have suggested that
increased BDNF levels are associated with risks for coronary heart
disease [26–28]. BDNF is expressed in smooth muscle cells,
macrophages and extracellular matrix of diseased cardiac tissue
[19] and pretreatment with BDNF can lead to increased
myocardial injury in a rat model of myocardial infarction [29].
Our results further support the association between BDNF levels
and cardiac disease. In females, increased BDNF levels were
associated with increased diastolic blood pressure (p=0.0486,
R
2=0.01666), increased LDL (p=0.0139, R
2=0.02634), in-
creased cholesterol (p=0.0040, R
2=0.03487), increased fat mass
(p=0.0490, R
2=0.01825) and increased BMI (p=0.0396,
R
2=0.01843; Figure 2 and Figure 3). In males, increased BDNF
levels were associated with increased diastolic blood pressure
(p=0.03, R
2=0.0197) and increased triglycerides (p=0.0289,
R
2=0.02016; Figure 4A, B, Table 2). The association of these risk
Figure 1. Plasma BDNF, gender and age. A. Plasma BDNF was significantly higher in females than in males (p,0.05). B and C. Multiple linear
regression revealed that plasma BDNF was inversely correlated with age in males (p=0.0501, R
2=0.01577) and in females (p=0.0220, R
2=0.02244).
doi:10.1371/journal.pone.0010099.g001
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either a reactive protective role of BDNF in response to the
pathophysiology or a contributory role in the etiology of the
disease itself.
Plasma BDNF and folate
BDNF was negatively correlated with folate levels in female
subjects (p=0.0396, R
2=0.01885, Figure 2D, Table 2). Folate,
also referred to as folic acid or vitamin B9, is essential for red blood
cell production and the prevention of anemia. Additionally, folate
is needed to prevent the accumulation of homocysteine.
BDNF is associated with sex hormone levels in males
In male subjects we observed significant associations of BDNF
with bioavailable testosterone (BT) and sex hormone binding
globulin (SHBG). There was a significant positive correlation
between BDNF and BT; males with higher BDNF levels tended to
have more BT (p=0.0443, R
2=0.01755; Figure 4C, Table 2).
The majority of circulating testosterone in the body is bound to
SHBG, thus one would expect to see opposite changes in levels of
these two hormones. Indeed, in our study subjects, males with
higher BDNF tended to have lower SHBG (p=0.0150,
R
2=0.03489; Figure 4D, Table 2). Typically during aging, BT
tends to decrease while SHBG increases [30].
BDNF is associated with multiple metabolic hormones in
males
Adiponectin is an adipose derived hormone that modulates
glucose regulation and fatty acid catabolism. We observed a
significant negative correlation between BDNF and adiponectin in
male subjects (p=0.0137, R
2=0.0465). Males with higher plasma
BDNF tended to have lower plasma adiponectin levels (Figure 5B,
Table 2). A positive correlation was seen between BDNF and free
triiodo-thyronine (FT3) in male subjects (p=0.0053,
R
2=0.03348; Figure 5A, Table 2).
Plasma BDNF and glycemic sensitivity
In our aged individual samples, a positive correlation was
demonstrated between male BDNF plasma levels and glucose
levels 120 minutes after an oral glucose bolus (p=0.0460,
R
2=0.02170), further suggesting a role for BDNF in metabolic
function (Figure 5C, Table 2). However, we did not find a
correlation between fasting plasma glucose and plasma BDNF.
Variables measured, but not significantly correlated with
plasma BDNF levels
In addition to the factors measured that did exhibit significant
correlations with plasma BDNF levels in males and/or females, we
also measured a range of additional factors for which no
statistically significant correlation with BDNF levels was obtained
in either males or females (Supplementary Table S1). These
included HDL, cholesterol, vitamin B12, ferritin, total iron,
homocysteine, uric acid, lactate dehydrogenase, body weight,
fasting glucose, resistin, FT4, T4, TSH and total testosterone. We
also normalized our data set for body mass index (BMI), to further
determine relationships between BDNF and cardiovascular and
metabolic factors. BMI is considered to be an imperfect measure
because it does not assess body fatness directly [31]. Due to this, its
use in epidemiologic studies has been recently criticized [32–34]. It
has been demonstrated that for example with respect to a
profoundly declarative outcome such as mortality, that weak or
negative associations between BMI and mortality are due to the
lack of the ability of BMI to discriminate between lean and fat
mass and that more accurate and nuanced assessments of body-
type are required [35]. Indeed the predictive capacity of long-term
health outcomes using BMI-rankings can skew data and result in
misleading findings [36]. When normalizing for BMI, in females
plasma BNDF levels were negatively correlated with leptin
(p=0.0790) and uric acid (p=0.020) and in males, BDNF was
negatively correlated with age (p=0.055) and positively correlated
with weight and uric acid levels (p=0.079, p=0.063 respectively).
It is presently unclear which factors, either directly or indirectly,
interact with BDNF and further work is needed to elucidate the
complex metabolic endocrine networks that involve or affect
BNDF.
Discussion
The neurotrophic factor, BDNF, has in recent years been the
subject of considerable interest primarily for its roles in
developmental and synaptic plasticity, and as a neuroprotective
factor for multiple aging-related neurodegenerative disorders [3].
However, evidence is scant regarding the function of BDNF
outside of the CNS. Our data from middle age and elderly subjects
in the BLSA demonstrated that plasma BDNF levels are
significantly associated with several key indicators of metabolic
and cardiovascular health. These results reinforce an increasing
body of evidence indicating regulatory roles for BDNF in
metabolism and cardiovascular homeostasis. Higher plasma
BDNF levels were associated with risk factors for cardiovascular
disease including elevated diastolic blood pressure and triglycer-
ides in men and elevated diastolic blood pressure, total and LDL
cholesterol, BMI and fat mass in women. Although the
correlations reported in our study are robust, we cannot derive
any conclusions on the specific nature of these associations. It is
possible that BDNF contributes to the pathophysiology of
Table 2. Linear Regression analysis of plasma BDNF and
metabolic and cardiovascular dysfunction risk factors,
measured in males and females in the BLSA cohort.
Variable p-value F value DFn, DFd R
2
Male
Diastolic blood pressure 0.0300 4.765 1.000, 237.0 0.01971
Triglycerides 0.0289 4.834 1.000, 235.0 0.02016
Bioavailable Testosterone 0.0443 4.092 1.000, 229.0 0.01755
SHBG 0.0150 6.037 1.000, 167.0 0.03489
FT3 0.0053 7.932 1.000, 229.0 0.03348
Age 0.0501 3.878 1.000, 242.0 0.01577
Adiponectin 0.0137 6.242 1.000, 128.0 0.04650
Glucose-120 0.0460 4.037 1.000, 182.0 0.02170
Female
Diastolic blood pressure 0.0486 3.930 1.000, 232.0 0.01666
LDL 0.0139 6.142 1.000, 227.0 0.02634
Cholesterol 0.0040 8.455 1.000, 234.0 0.03487
Folate 0.0396 4.285 1.000, 223.0 0.01885
Fat mass 0.0490 3.922 1.000, 211.0 0.01825
BMI 0.0396 4.282 1.000, 228.0 0.01843
SHBG, sex-hormone binding globulin; FT3, Free triiodo-thyronine T3; LDL, low
density lipoprotein; BMI, bodymass index.
doi:10.1371/journal.pone.0010099.t002
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PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10099Figure 2. Linear regression analysis correlating plasma BDNF and markers of cardiovascular risk in females. A, B and C. Plasma BDNF
was positively correlated with diastolic blood pressure (p,0.05, R
2=0.0228), LDL-cholesterol (p=0.139, R
2=0.02634), and total cholesterol
(p=0.0040, R
2=0.03487). D. Folate levels were inversely correlated with plasma BDNF (p=0.0396, R
2=0.01885).
doi:10.1371/journal.pone.0010099.g002
Figure 3. Linear regression analysis of plasma BDNF, fat mass and BMI in females. A and B. Plasma BDNF was positively correlated with fat
mass (p=0.0490, R
2=0.01825) and BMI (p=0.0396, R
2=0.01843).
doi:10.1371/journal.pone.0010099.g003
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compensatory response to an underlying disease processes.
We found that plasma BDNF levels decrease with age in both
males and females, which is similar to what has been reported
previously [37]. The specific source of plasma BDNF is unknown.
In addition to the central and peripheral nervous system, BDNF is
also stored in circulating platelets and is found in muscle, heart
and gonads [19,38–40]. The exact reason for a decrease in plasma
BDNF levels with aging is unclear. Considering that the
prevalence of metabolic syndrome, type 2 diabetes, obesity,
coronary artery disease and hypertension increases as individuals
get older, it is possible that BDNF functions as a protective factor
against metabolic and cardiovascular disorders, and that decreased
peripheral BDNF synthesis, secondary to aging, renders individ-
uals more susceptible to these conditions. In regards to metabolic
dysfunction and aging, it has been suggested that the connection
between energy regulation and increasing age may also be
controlled by alterations in BDNF levels [41]. Furthermore, low
plasma BDNF levels may be linked to increased mortality. Data
from the Danish National Register of Patients indicated a
significantly greater all-cause mortality risk in elderly women with
low plasma BDNF levels, independently of education, CNS
disease, cardiovascular disease, cancer, respiratory disease and
low-grade inflammation [42].
Similarly to the sex-differences that have been described for
leptin [43], we found that plasma BDNF levels were significantly
higher in women than in men. Additionally, we also found that
plasma BDNF levels correlated positively with BMI and fat mass
in women, but not in men. Unlike leptin, however, BDNF has not
been shown to be secreted by adipocytes. Recently, a small study
of 18 women undergoing bariatric surgery followed by successful
weight loss showed that plasma BDNF levels were significantly
decreased 3 months postoperatively [44], which corroborates our
finding of a positive correlation between BMI and plasma BDNF
levels. The higher levels of plasma BDNF associated with an
increased fat mass could potentially reflect a systemic low-grade
inflammatory state. It has recently been demonstrated that even
non-obese individuals with moderate abdominal adiposity have
higher plasma C-reactive protein (CRP) levels than BMI-matched
controls [45]. As proinflammatory cytokines can stimulate BDNF
secretion from monocytes, the elevated plasma BDNF levels could
indicate an inflammatory state associated with greater adiposity
[46]. Moreover, we found that plasma adiponectin was inversely
correlated with plasma BDNF levels in males. Rodent and human
Figure 4. Linear regression analysis correlating plasma BDNF and markers of the metabolic syndrome in males. A, B and C. Plasma
BDNF was positively correlated with diastolic blood pressure (p=0.0300, R
2=0.01971), triglycerides (p=0.0289, R
2=0.02016), and bioavailable
testosterone (p=0.0443, R
2=0.01755). D. Plasma BDNF was inversely correlated with SHBG (p=0.0150, R
2=0.03489).
doi:10.1371/journal.pone.0010099.g004
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stress such as obesity and type-2 diabetes, while weight loss
increases plasma adiponectin levels [47]. For the female subjects,
the data was not corrected for estrogen replacement therapy due
to lack of information and reliable data on estrogen replacement
status in the BLSA. Future studies are needed to elucidate these
relationships further.
Another known risk factor for metabolic syndrome, type 2
diabetes and coronary artery disease is male hypogonadism. In
addition, decreased levels of plasma SHBG have also been
implicated in both insulin resistance and metabolic syndrome [37].
It has also been proposed that SHBG may act as a regulator of
lipid metabolism [48]. We found that bioavailable testosterone
levels were directly correlated to plasma BDNF levels in males,
and the opposite occurred for SHBG, indicating that plasma
BDNF could play a role in the pathogenesis of metabolic and
cardiovascular disorders in male hypogonadism. In males, we also
found that levels of the unbound form of the thyroid hormone
triiodothyronine (T3) were positively correlated with plasma
BDNF levels. T3 is an orexigenic hormone that plays an important
role in metabolic regulation [49]. T3 has various peripheral
metabolic actions, which include regulation of hepatic gluconeo-
genesis, lipogenesis, and glucose transporter expression in skeletal
muscle [50]. A recent study demonstrated that T3 is involved in
the regulation of BDNF gene expression in hypothalamic areas
involved in energy balance [51], indicating a potential interface
between T3 and BDNF. It has also been shown that treatment
with T3 can increase the expression of hypothalamic neuropeptide
Y (NPY) mRNA, while reducing hypothalamic pro-opiomelano-
cortin (POMC) and cocaine and amphetamine-regulated tran-
script (CART) mRNA levels [52]. NPY, CART and POMC are
satiety factors, and NPY is known to regulate energy balance, food
intake and physical activity. CART has been closely associated
with the action of two important regulators of food intake, leptin
and NPY [53].
The significant correlation between plasma BDNF, plasma
lipids and diastolic blood pressure in both males and females
strongly suggests that plasma BDNF is important for cardiovas-
cular health. In addition to potentially playing a direct role in
atherogenesis, plasma BDNF may be a regulator of lipid
metabolism and blood pressure control. Dislipidemia and
hypertension are major risk factors for coronary heart disease.
Whether the associations described above are causal or whether
elevated plasma BDNF represents a compensatory response to
disrupted lipid metabolism and hypertension is presently unclear.
It remains to be elucidated if the link between dislipidemia and
Figure 5. Linear regression analysis correlating plasma BDNF with thyroid function, adiponectin levels and glucose sensitivity in
males. A and C. Plasma BDNF was positively correlated with FT3 (p=0.0053, R
2=0.03348) and glucose-120 (p=0.0460, R
2=0.02170). B. Plasma BDNF
was inversely correlated with plasma adiponectin (p=0.0137, R
2=0.04650).
doi:10.1371/journal.pone.0010099.g005
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our study, plasma folic acid levels were inversely correlated with
plasma BDNF levels in women. Folate deficiency is the most
common nutritional cause of hyperhomocysteinemia, a well-
established risk factor for atherogenesis and thrombosis [54].
The relationship between BDNF and glucose regulation is
intricate. We found that the 2-hour blood glucose time-point,
following an oral glucose load, was positively correlated with
plasma BDNF levels. It has been shown recently that plasma
BDNF levels are reduced in patients with type 2 diabetes
(independently of obesity), and are inversely correlated with
fasting plasma glucose [55]. Additionally, serum levels of BDNF
have also been shown to be decreased in patients with type 2
diabetes compared to healthy controls [56].
In complex biological systems, coordinated metabolic functions
are created by the summation of multiple inter-connected
pathways forming networks of varying sizes and relative
importance [57–59]. Thus the ability to apply significance of
predicted functional output no longer rests upon individual factors
but on co-presentation and coherent regulation of these factors,
reflecting the coordinated, interconnected nature of metabolic
pathways themselves. It is highly likely that a simple resultant
physiologically-measured parameter, such as blood pressure or
serum triglycerides, can be related to small, often non-statistically
significant, coherent actions of multiple factors that together
generate the measured effect. All the factors that we measured
typically fell into two functional categories, metabolic factors and
cardiovascular factors. Thus, even though the statistical signifi-
cance of the correction of each factor individually with BDNF is
often small, all those factors acting synergistically together will
likely elicit a significant biological phenotype. This concept of
inter-connectivity is currently being applied in genomic analyses,
where often small, non-significant gene changes that occur
together can elicit large clinically-relevant phenotypic outputs
[60–64]. In future studies, this idea of connectivity will also likely
be applied to clinical studies.
The aging process and many of its associated diseases all involve
perturbed energy metabolism. The control of food intake, glucose
regulation and metabolism is dependent upon a fine balance
between central regulatory inputs (primarily orchestrated by the
hypothalamus), and a multitude of peripheral signals, such as
insulin, adipokines (e.g. leptin, adiponectin, resistin), and gut
hormones (e.g. cholecystokinin and ghrelin). The crosstalk
between these myriad pathways subserves the control of energy
balance, stress responses and cardiovascular function. It is
becoming apparent that BDNF plays an important regulatory
role within this complex and dynamic system, and that the specific
roles of BDNF in controlling and maintaining peripheral
metabolic and cardiovascular health require further investigation.
Alterations in peripheral BDNF signaling could potentially be a
common denominator for the metabolic syndrome spectrum,
which ranges from impaired glucose tolerance to overt diabetes, to
mild atherogenesis to clinical coronary artery disease. Gaining a
greater understanding of plasma BDNF’s potential multifaceted
roles in both the periphery and the CNS will be fundamental for
advancing our knowledge of mechanisms underlying metabolic
disorders and for the development of novel therapies that can
modify BDNF levels in specific target tissues.
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